Background: American Society of Clinical Oncology guidelines recommend the use of growth factor after high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support. This randomized trial aims to demonstrate the noninferiority of pegfilgrastim (PEG) compared with filgrastim (FIL) after HDC.
introduction High-dose chemotherapy (HDC) with autologous stem cell support is widely accepted as standard of care in many hematological malignancies and some solid tumors.
Peripheral blood stem cell (PBSC) has substituted bone marrow as stem cell source, with a significant advantage on several clinical end points in large randomized studies [1, 2] .
Growth factor administration, mainly granulocyte colonystimulating factor [G-CSF, filgrastim (FIL) or lenograstim], after PBSC has been reported to further reduce the time to reach a safe neutrophil count with additional benefits in some studies [3] [4] [5] [6] . Nevertheless, the quicker hematological reconstitution did not translate into reduction of clinically significant events, such as infections, mortality, time spent in hospital, or extra-hematological toxic effects in other studies [7] [8] [9] . However, the American Society of Clinical Oncology (ASCO) guidelines recommend the use of growth factor after PBSC infusion [10] .
Pegfilgrastim (PEG) is synthesized by adding a 20 kDa polyethylene glycol moiety to FIL. This process modifies the pharmacokinetics and pharmacodynamic proprieties: longer half-life and slower elimination rate with consequent higher plasma concentration [11] . One single dose of PEG was shown to be as effective as FIL and sometimes superior to FIL in reducing the length of severe neutropenia and related clinical complications in animal models [12] and in cancer patients treated with conventional dose chemotherapy [13] [14] [15] [16] [17] . PEG after HDC and PBSC has been evaluated in retrospective, single-arm phase II study or case-control study, all indicating that the pegylated provided a similar efficacy to FIL in hematological reconstitution rate [18] [19] [20] [21] [22] [23] [24] . The purpose of this randomized trial was to prove the noninferiority of a fixed-dose PEG compared with daily FIL, both administered the day after autologous PBSC infusion, in patients receiving HDC. 
patients and methods

From
study design
This was an open-label randomized study. The aim of this study was to demonstrate that fixed-dose PEG was not inferior to daily dose FIL administered after autologous PBSC infusion. The primary end point was the duration of severe neutropenia both in terms of absolute neutrophil count (ANC <0.5 · 10 9 /l) and of number of days to achieve an ANC >0.5 · 10 9 /l starting from the day +1. Secondary end points were the number of days to achieve an ANC >1.0 · 10 9 /l starting from day +1, number of days with fever >38°C, duration of antibiotic and antimycotic therapy, and number of documented infections.
treatment plan
In the experimental arm, a single, s.c. fixed dose (6 mg) of PEG was administered 24 h after autologous PBSC infusion (day +1).
In the control arm, a s.c. weight-based daily dose (5 lg/kg/day) of FIL was administered from day +1 until ANC recovery to >0.5 · 10 9 /l for two consecutive days.
supportive care
Each center followed local and/or international guidelines for supportive care, such as antibiotic, antiviral, and antifungal prophylaxis; antibiotic treatment; and transfusion policy. However, all patients received at least quinolone prophylaxis.
statistical methods
Statistical analysis was done for the intention to treat (ITT) (N = 80) and for the modified ITT (MITT) (N = 77), excluding three patients with major protocol violations. In order to verify the noninferiority of PEG, it was assumed that with FIL the mean duration of ANC <0.5 · 10 9 /l was 8 days with a standard deviation (SD) of 1.3, as reported in literature. We established a value for the standardized mean difference of 0.75, leading to consider 9 days as acceptable for the PEG group. Considering a value of 0.025 and a power of 90%, 80 patients were required. Results of the analysis showed that the assumption about SD was not reflected in the study population that presented a SD of 2.2; in order to maintain the same standardized mean difference of 0.75, the delta value was increased from 1 to 1.65 days.
The same analysis was carried out for all the secondary variables that were clinically correlated with ANC expression, fixing the standardized mean difference of 0.75 and recalculating for each variable the value of delta on the basis of the standard error found in the study population. Corresponding to the noninferiority design, results are presented as differences in means with their 95% confidence intervals (CIs). PEG was considered not inferior to FIL if the upper two-side 95% CI for the ANC mean difference was less than the corresponding noninferiority margin of delta.
All variables not strictly related to ANC level were analyzed with a superiority test. Categorical data were summarized as frequencies and proportions with 95% CI comparing treatment groups by using the chi-square test or the Fisher's exact test when appropriated. Mean (95% CI) or median (range) values were used to summarize continuous variables and comparisons between the two groups were made by using the Student's t-test. A P value of 0.05 was considered to be the limit of statistical significance. All calculations were carried out using R software.
Mean (95% CI) or median (range) values were used to summarize continuous variables and comparisons between the two groups were made by using the Student's t-tes or the Wilcoxon test, respectively.
results
Patient characteristics are shown in Table 1 . There were no statistical differences between the two groups for all variables at inclusion.
Overall, 77 patients were suitable, 3 patients were excluded: 1 patient (in FIL arm) progressed after randomization and before HDC, 1 patient (in PEG arm) received FIL at day +5, and 1 patient received bone marrow stem cells instead of peripheral stem cells. Three patients received a lower CD34 positive number than required per protocol (two in FIL and one in PEG arm). Statistical analysis was carried out in ITT and all patients were analyzed. A MITT analysis, excluding these three patients, was also carried out. Both analyses provided the same results and thus we present only the ITT analysis.
PEG was not inferior to FIL considering the primary end point in terms of both the duration of ANC <0.5 · 10 9 /l and the time to reach an ANC >0.5 · 10 9 /l. Indeed, the upper two-side 95% CI for the difference in the duration of ANC <0.5 · 10 9 /l The upper two-side 95% CI for the difference in time to reach ANC >0.5 · 10 9 /l was less than the noninferiority margin of delta of 3.64, presenting a mean value of 20.78 with a 95% CI of 22.97 to +1.42. Similarly, the noninferiority analysis carried out on the other variables related to primary end point, such as time to reach ANC >1.0 · 10 9 /l and days with fever, confirmed the noninferiority for PEG compared with FIL, as reported in Table 2 . A superiority analysis was carried out with regard to hematological (Table 3) and nonhematological (Table 4 ) toxic effects and days to discharge. No significant differences were observed between the two groups for all variables analyzed. No differences were observed in mean duration of antibiotic therapy (mean 5.7 versus 4.0 days, P = 0.152, respectively in FIL and PEG arms).
In the FIL arm, the median daily dose of FIL was 340 lg (range 265-500 lg) and the median number of vials per patient was 20 (range 7-52). The median duration of treatment was 10 days (range 6-51 days).
discussion
The use of G-CSF after HDC and PBSC reinfusion has been widely evaluated in several prospective randomized studies [4] [5] [6] [7] [8] [9] . Overall, these studies demonstrate an advantage in the G-CSF arm with reductions in the time to ANC recovery. Questions on the optimal timing for starting G-CSF after reinfusion have been addressed in some studies, yet a clear advantage in giving G-CSF on day +1 [18] [19] [20] [21] or on days +3 and +5 [25] , and on day +7 [19] has not been evidenced. However, in a retrospective study [25] , it has been strongly indicated that the number of CD34-positive cells reinfused would be a reliable criterion to consider or not the use of G-CSF. Nonetheless, the ASCO guidelines [10] recommend to administer G-CSF starting on day +1 after PBSC reinfusion.
Some nonrandomized studies [18, 19, 22] reported on the role of PEG after PBSC reinfusion both in lymphoma and in myeloma. Overall, these studies demonstrated a similar hematological reconstitution when compared with historical G-CSF cohorts. Only one previous small randomized study compared FIL (5 lg/kg) with PEG (6 mg) at day +1 in a very limited number of myeloma patients [21] and showed that the hematopoietic recovery was comparable.
Our study is the largest randomized trial comparing the efficacy of PEG versus FIL in the hematological reconstitution after HDC and PBSC in patients with hematological malignancies and solid tumors. Our data clearly indicate that a single fixed dose of PEG is not inferior to daily weight-based dose FIL with respect to the time to reach an ANC >0.5 · 10 9 /l (10.8 versus 11.5 days) as well as to the duration of ANC <0.5 · 10 9 /l (6.20 versus 5.97 days). Furthermore, no differences were observed in terms of infections and time to discharge from the hospital. The number of platelet (PLT) transfusions was superimposable in the two arms, even if a trend to a shorter time to reach a PLT count >20 000 was observed in the PEG arm (PEG versus FIL: 4.2 versus 6.3).
No additional extra-hematological toxicity was observed in the PEG group and the side effects were similar in the two arms (Table 4) . In conclusion, this randomized trial clearly showed that PEG at a fixed dose of 6 mg at day +1 after HDC and PBSC is as effective and safe as daily weight-based FIL in accelerating the hematopoietic recovery. These data strongly indicate that PEG represents an effective alternative to FIL after HDC with PBSC support.
note
This trial was registered at www.clinicaltrials.gov at NCT00410696.
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